Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Issue 4 (17th November 2006)

• Record Type: Journal Article
• Authors: Kavanaugh, A; Krueger, G G; Beutler, A; Guzzo, C; Zhou, B; Dooley, L T; Mease, P J; Gladman, D D; de Vlam, K; Geusens, P P; Birbara, C; Halter, D G; Antoni, C
• Other Names: group-author.
• Is Part Of: Annals of the rheumatic diseases. Volume 66:Issue 4(2007)
• Page Start: 498
• Page End: 505
• Publication Date: 2006-11-17
• Subjects: ACR, American College of Rheumatology -- AE, adverse event -- ALT, alanine aminotransferase -- anti dsDNA, antibodies to double stranded DNA -- AST, aspartate aminotransferase -- ANAs, antinuclear antibodies -- BSA, body surface area -- HAQ, Health Assessment Questionnaire -- MTX, methotrexate -- NSAIDs, non-steroidal anti-inflammatory drugs -- PASI, Psoriasis Area and Severity Index -- PsA, psoriatic arthritis -- PsARC, Psoriatic Arthritis Response Criteria -- SAE, serious adverse effect -- SF-36, Short Form-36 -- TNFα, tumour necrosis factor α; infliximab -- psoriatic arthritis -- tumour necrosis factor α -- ACR 20 -- PASI 75; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2006.058339
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objective: To evaluate the efficacy and safety of infliximab through 1 year in patients with psoriatic arthritis (PsA) enrolled in the IMPACT 2 trial. Methods: In this double blind, placebo controlled, phase III study, 200 patients with active PsA were randomised to receive infusions of infliximab 5 mg/kg or placebo at weeks 0, 2, 6, and every 8 weeks thereafter through 1 year. Patients with persistent disease activity could enter early escape at week 16, and all remaining placebo patients crossed over to infliximab at week 24. Patients randomised to infliximab who had no response or who lost response could escalate their dose to 10 mg/kg starting at week 38. Clinical efficacy was assessed based on the proportion of patients achieving ACR 20 and PASI 75 responses. Major clinical response (that is, maintenance of ACR 70 response for 24 continuous weeks) was assessed for the first time in PsA. Results: Through 1 year of treatment, 58.9% and 61.4% of patients in the randomised infliximab and placebo/infliximab groups, respectively, achieved ACR 20; corresponding figures for PASI 75 were 50.0% and 60.3%. At week 54, major clinical response was achieved by 12.1% of patients in the infliximab group. The safety profile of infliximab through week 54 was consistent with that seen through week 24. Two malignancies occurred: basal cell skin cancer (placebo) and stage I Hodgkin's lymphoma (infliximab). Conclusion: Infliximab maintains a high degree of clinical efficacy and continues to be well tolerated in patients with PsA through 1 year of treatment.